Drug
Relebactam clinical trials
Also written MK-7655.
- studies test it
- 13
- open now
- 1
- in phase 3
- 6
- first study started
- 2012
Keep track of what changes. Save the relebactam studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
13 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2015 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 2 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 4
- Phase 3
- 6
- Phase 4
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 5
Merck Sharp & Dohme LLC (8) · M.D. Anderson Cancer Center (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Hartford Hospital (1) · University of Illinois at Chicago (1) · Wake Forest University Health Sciences (1)
Often tested with
Tested in the same studies.
Imipenem (11) · Cilastatin (9) · Avibactam, ceftazidime drug combination (1) · Meropenem and vaborbactam (1) · Cefiderocol (1) · Aztreonam (1) · Eravacycline (1) · Aztreonam, avibactam drug combination (1)
Studies
Open first, then newest update. How each study uses relebactam is read from its arms, and is right about nine times in ten.
Testing it · 13
- Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationNot yet recruitingPhase 3IRCCS Azienda Ospedaliero-Universitaria di BolognaNCT07759453Written as Imipenem+Relebactam
- PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONINCompletedPhase 2M.D. Anderson Cancer CenterNCT04983901Written as Imipenem/Cilastatin/Relebactam
- Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)CompletedPhase 2/3Merck Sharp & Dohme LLCNCT03969901Written as IMI/REL
- Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (MK-7655A-016)CompletedPhase 3Merck Sharp & Dohme LLCNCT03583333Written as IMI/REL FDC
- Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic FibrosisTerminatedPhase 4Hartford HospitalNCT05561764Written as Imipenem/Cilastatin/Relebactam
- Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU PatientsWithdrawnPhase 4University of Illinois at ChicagoNCT05146154Written as Imipenem/Cilastatin/Relebactam 1.25g
- Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE InfectionsWithdrawnPhase 4Wake Forest University Health SciencesNCT04785924Written as Imipenem+Relebactam
- A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT03230916Written as IMI/REL FDC
- Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)CompletedPhase 3Merck Sharp & Dohme LLCNCT03293485Written as Imipenem+Cilastatin/Relebactam
- Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)CompletedPhase 3Merck Sharp & Dohme LLCNCT02493764Written as Relebactam
- Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)CompletedPhase 2Merck Sharp & Dohme LLCNCT01506271Written as Relebactam 250 mg
- Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01505634Written as Relebactam 250 mg
- Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)CompletedPhase 3Merck Sharp & Dohme LLCNCT02452047Written as Imipenem+Cilastatin/Relebactam
Given in every arm · 1 — relebactam is usual care beside what is tested
As the comparator · 1 — what is tested is compared with relebactam
Codes
What other systems call relebactam · ClinicalTrials.gg INT005942
- MeSH (NLM) C568736relebactamConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) Y1MYA2UHFLRELEBACTAMConfirmed FDA, NLM, Wikidata
- Wikidata Q27294146relebactam monohydrateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152176Relebactam MonohydrateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C568736 | relebactam | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | Y1MYA2UHFL | RELEBACTAM | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294146 | relebactam monohydrate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152176 | Relebactam Monohydrate | One source FDA |
Also registered as relebactam anhydrous (UNII 1OQF7TT3PF).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.